). Treatment of Epo-responsive Rauscher erythroleukemia cells with an anti-sense oligodeoxynucleotide to c-myb in the absence of other inducers downregulated myb protein markedly and caused hemoglobiniration of the cells within 48 hours. Epo treatment, which downregulates c-myb in these H E PROTO-ONCOGENES c-myb and c-myc have The publication costs of this article were defrared in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section I734 solely to indicate this fact. 0 I991 by The American Society of Hematology. 0006-4971 /91/7804-002 7$3. 0010 Blood, Vol78, No 4 (August 15). 1991: pp 991-996
T been implicated in the regulation of differentiation of hematopoietic cells. Chemical inducers rapidly alter the steady state levels of these transcripts in transformed erythroid cells.'x2 Moreover, transfected cell lines containing stably (constitutively) expressed c-myc or c-myb in addition to the endogenous gene apparently are unable to differentiate in response to chemical inducer^.^.^ In contrast, constitutive expression of mbm2, an alternately spliced c-myb messenger RNA (mRNA) encoding a truncated p7YmY* found in some Friend erythroleukemia cells, results in enhanced hemoglobinization when the cells are exposed to chemical inducers. '
The role of these proto-oncogenes in the differentiation pathway triggered by erythropoietin (Epo) has not been well defined. Todokoro et a1 showed that Epo treatment of a murine erythroleukemia cell line resulted in downregulation of c-myb expression and that this downregulation appeared necessary for Epo-induced hemoglobinization of these cells.* Recently, we demonstrated that Epo downregulates c-myb in both Rauscher and Friend murine erythroleukemia cells9 and that c-myc and c-myb are early response genes for Epo.""
The combined observations that both chemical inducers and Epo downregulate c-myb and that interference with this downregulation blocks hemoglobinization have provided strong, albeit indirect, evidence for the functional importance of c-myb in erythropoiesis. We have now obtained direct evidence, using antisense oligodeoxynucleotide (oligo) treatment of Rauscher cells, that downregulation of c-myb and myb protein induces hemoglobin synthesis to the same degree as does Epo.
MATERIALS AND METHODS

Cell growth and oligodeonynucleotide treatment.
Rauscher cells (clone EMSIII)'' were cultured in 96-well plates, 1,500 cells/well (100 pL) in the absence or presence of 10 U recombinant human Epo (rhuEpo)/mL (Elanex Pharmaceuticals, Bothell, WA). Oligo (0-oligo or S-oligo), 40 &mL, was added followed by a second addition of 10 pg/mL after 24 hours. Hemoglobinized cells (Hb') were scored by benzidine staining" after 48 hours (200 cells scored). Points represent mean 2 SD. Oligos were synthesized using an Applied Biosystems (Foster City, CA) DNA Synthesizer 380A and were purified by ethanol precipitation.
After incubation with oligo, cells were harvested and centrifuged onto glass slides, fixed with acetone at room temperature, and stored at -20°C. Slides were thawed and fixed in acetone for 10 minutes at Immunocytochemical identijication of mybprotein. cells, induced hemoglobinization to the same degree. Epo also induced the appearance of anion transport protein on the plasma membrane, consistent with terminal differentiation. In contrast, antisense c-myb did not induce this erythroid marker. The results are consistent with a role for myb protein in the regulation of hemoglobin synthesis. 0 1991 by The American Society of Hematology.
4"C, and then stained with monospecific anti-myb monoclonal antibodies (MoAbs) generated against a synthetic peptide corresponding to amino acids 94-112 of v-myb (Microbiological Associates, Bethesda, MD) as described."
Rauscher cells were plated in suspension culture at 1 x lo5 cellsimL and were treated with oligo (40 p g h L for 18 hours). Ten microliters of the cell suspension was added to 90 FL of plasma clot medium in 96-well plates and incubated for 3 days at 37°C (4 wellsidetermination). The clots were removed onto glass slides, fixed, and ~tained.~'.'~
Plasma clot cultures.
RESULTS
We treated Epo-responsive Rauscher cell^^^'^^'^^'^^'^^'^ with an anti-sense oligo complimentary to codons 2 through 7 of mouse c-myb" (Fig 1) . After 48 hours of incubation, 17% of the cells were hemoglobinized (Hb+). Treatment of replicate cultures with Epo instead of the oligo also yielded 17% Hb+ cells. Exposure of the cells to both anti-sense c-myb oligo and Epo simultaneously yielded 18% Hb' cells. The absence of an additive effect of anti-sense c-myb oligo and Epo strongly suggests that both agents were probably operating on the same responsive population of cells. Importantly, addition of antisense c-myc, anti-sense vesicular stomatitis virus M protein (vsv),I8 or a nonsense sequence with the same base composition as anti-myb as control oligos did not induce Hb' cells. Addition of anti-vsv oligo plus Epo resulted in 10% Hb' cells. Similar results were obtained in two other experiments. The ability of anti-sense c-myb to induce hemoglobin synthesis in these cells was concentration dependent and was also demonstrable with an S-oligo (Fig 2) . Addition of 20 pg or 40 pLgimL of anti-sense c-myb S-oligo for 48 hours yielded 5% and 12% Hb' cells, respectively. Control oligo was again without effect.
We demonstrated that anti-sense c-myb oligo decreased myb protein using an antipeptide MoAb. A high concentration of the myb protein was found in the cytosol of Rauscher cells (Fig 3A) . Although myb protein binds.DNA and has been found concentrated in the nucleus of some cell^,'^.^^ other cells, including normal T lymphocytes, exhibit higher cytosolic concentrations very similar to that shown here.19 Importantly, treatment of Rauscher cells with anti-sense c-myb drastically reduced the myb protein concentration in the cells (Fig 3B) , confirming the efficacy of the treatment.
We considered the possibility that anti-sense c-myb oligo might trigger hemoglobin synthesis in a cell and simultaneously arrest further proliferation of that cell (see Discussion). To test this possibility, we treated cells in suspension culture for 18 hours and then transferred them to plasma clot c u l t~r e '~~'~ to permit examination of Hb' daughter cells arising in colonies. In the absence of inducer or in the presence of control oligo only 2.6% of colonies were Hb'. Most contained no Hb' cells ( Fig 4A, Table 1 ). However, anti-sense c-myb oligo or Epo resulted in 20% and 21% Hb+ colonies, respectively (Fig 4B, Table 1) . Importantly, the plating efficiencies observed under all treatment conditions were identical (15% 2 2%), as were the sizes of the colonies. Thus, we found no evidence for a growthinhibiting action of the anti-sense c-myb on Rauscher cells. Although anti-sense c-myb oligo treatment clearly resulted in hemoglobin synthesis, it did not induce expression of all mature erythrocyte characteristics ("terminal differentiation"). We determined this by staining for the membrane anion transport protein, band 3." Epo treatment resulted in the appearance of band 3 on 19% of the cells. However, we did not detect the band 3 on cells treated with the anti-sense c-myb oligo (not shown).
DISCUSSION
Myb protein is a DNA binding protein that regulates transcription either positively or negatively." Positive regulation appears to occur by two different mechanisms, involving either sequence-specific or sequence-nonspecific binding of the pr~tein.'~ Studies of the role of c-myb in hematopoiesis using anti-sense oligos have shown an arrest or reduction of hematopoietic growth accompanying reduction of c-myb. 24-21 However, we found no effect of anti-sense c-myb oligo on the growth of Rauscher cells. There are at least two possible explanations for this apparent contradiction. Firstly, most of the previous studies have examined the effect of c-myb reduction on the growth and differentiation of normal hematopoietic cells using colony assays requiring many days. As a result, these experiments are likely to encounter multiple effects of c-myb reduction that almost certainly must occur during progenitor differentiation. In addition, the study of normal progenitors requires the inclusion of appropriate growth factor(s) (eg, Epo), adding further complexity to the analysis. In contrast, in the present study we have used an erythroleukemia cell line that replicates independently and does not require Epo for growth. Therefore, we have been able to study the role of c-myb in erythroid differentiation separately from a potential role in growth factor-regulated cell proliferation and from Epo or other inducers. The use of a homogeneous cell population here has avoided the complexities inherent in the study of heterogeneous populations of normal cells, an approach that is made even more difficult by the possibility of pleiotropic effects of anti-sense oligo treatment on a variety of interacting cell types.
Although Epo regulates c-myc as well as c-myb expression,8-'o we observed no effect of antisense c-myc oligo either in the absence or presence of Epo. However, this finding does not rule out a role for c-myc in erythropoiesis. It may suggest that c-myc participates in Epo-induced cell proliferation rather than in differentiation. If so, our use of an independently proliferating Epo-sensitive cell line in these studies might be expected to result in an absence of We verified that the addition of excess peptide antigen blocked the staining of myb protein and that control oligo had no effect (not shown).
anti-sense c-myc effect. We have not been able to test whether the effects of reduction of myb protein on erythroid differentiation seen here are found also in nontransformed cells, due to the requirement of Epo for the cells' proliferation.
It should be noted that both Epo and anti-sense c-myb oligo induced hemoglobinization of individual cells (Fig 1) and of colonies (Table 1) to the same degree. We have taken this as evidence that the hormone and oligo are operating on the same population of responsive cells. Nonetheless, although myb protein appeared to be reduced in all cells treated with oligo, not all of the cells hemoglobinized. Such fractional response to induction appears to be an intrinsic property of erythroleukemia cells and is highly variable among different clones of the same line. This phenomenon was documented for dimethyl sulfoxide (DMSO) treatment of Friend erythroleukemia cells by Gusella et al" and for both Epo and DMSO treatment of 
B
Rauscher cells by o~rselves.'~ Its molecular basis is unclear. It appears to be related to the process of "commitment" that occurs with a certain time-dependent random probability (stochastically) during each cell cycle while in the presence of inducer. This concept arose from the classical studies of Till et al? who proposed that normal hematopoietic stem cell growth was governed by a stochastic process. Clearly, therefore, other factors besides inducer ("permissive factors") are involved in determining whether a cell will differentiate, and it is highly likely that some of these factors are intrinsic to the cell. We speculate that differential expression of other genes required for the cell to respond to inducer (Epo, DMSO, oligo) occurs among individual cells in a population and that the presence and relative abundance of the gene products (permissive factors) helps determine the cell's response to inducer. In this regard, we have found that Friend cells, which heretofore have been considered "Epo-nonresponsive," exhibit several responses to Epo identical to Rauscher cells, including specific membrane protein (pp43) dephosphorylation and See Fig 4. Values for anti-myb oligo and Epo are significantly greater *Colonies containing greater than 4 Hb' cells were scored a s Hb' than those for "none" or control anti-vsv oligo, P < .01.
colonies.
changes in c-myc and c-myb e~pression.~ Yet, Friend cells do not differentiate upon Epo treatment. This Friend cell "defect" may be due to the complete absence of one or more such permissive factors (gene products).
Our data support a role for c-myb in Epo-induced hemoglobin synthesis. However, reduction of myb protein did not trigger terminal differentiation. Rather, it was found to result in expression of a more limited repertoire of erythroid-specific genes. The possibility of regulation of a segment of the erythropoietic program by a single protooncogene product may be important in the design of specific therapies and suggests that the identification of other Epo early response genes should prove fruitful. For personal use only. on October 30, 2017. by guest www.bloodjournal.org From
